[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"rare-cancers\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:rare-cancers":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,60,102],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":32,"overallStatus":47,"whyStopped":4,"lastUpdateSubmitDate":48,"lastUpdatePostDateStruct":49,"startDateStruct":52,"completionDateStruct":54,"leadSponsor":56,"locationsCount":59},"100311904","phase-4-dabrafenib-andor-trametinib-rollover-study-100311904",false,"NCT03340506","Dabrafenib and\u002For Trametinib Rollover Study","Open Label, Multi-center Roll-over Study to Assess Long Term Safety in Patients Who Have Completed a Global Novartis or GSK Sponsored Dabrafenib and\u002For Trametinib Study","Inclusion Criteria:\n\n* Patient is currently receiving treatment with dabrafenib\u002Ftrametinib monotherapy or combination within a Novartis or former GSK sponsored study which has fulfilled the requirements for the primary objective.\n* In the opinion of the Investigator would benefit from continued treatment.\n\nExclusion Criteria:\n\n* Patient has been previously permanently discontinued from study treatment in the parent protocol.\n* Patient's indication is commercially available and reimbursed in the local country.\n* Patient currently has unresolved toxicities for which dabrafenib and\u002For trametinib dosing has been interrupted in the parent study.","ALL","18 Years","100 Years",{"count":20,"type":21},100,"ESTIMATED","INTERVENTIONAL",[24],"PHASE4","This study is to provide access for patients who are receiving treatment with dabrafenib and\u002For trametinib in a Novartis-sponsored Oncology Global Development, Global Medical Affairs or a former GSK-sponsored study who have fulfilled the requirements for the primary objective, and who are judged by the investigator as benefiting from continued treatment in the parent study as judged by the Investigator at the completion of the parent study.",[27,28,29,30,31],"Melanoma","Non Small Cell Lung Cancer","Solid Tumor","Rare Cancers","High Grade Glioma",[33,34,35,36,37,27,38,39,40,41,42,28,43,44,45,46,31],"Tafinlar","Mekinist","Dabrafenib","Trametinib","Adult","Melanoma Stage IV","Metastatic Melanoma","Advanced Melanoma","Lung Cancer","NSLC","BRAF V600 Mutation","BRAF Gene Mutation","Solid tumor","Rare cancers","RECRUITING","2026-06-22",{"date":50,"type":51},"2026-06-23","ACTUAL",{"date":53,"type":51},"2017-12-28",{"date":55,"type":21},"2032-12-28",{"name":57,"class":58},"Novartis Pharmaceuticals","INDUSTRY",31,{"id":61,"slug":62,"hasResults":11,"nctId":63,"briefTitle":64,"officialTitle":64,"acronym":65,"eligibilityCriteria":66,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":67,"targetDuration":4,"studyType":22,"phases":69,"briefSummary":71,"conditions":72,"keywords":75,"overallStatus":47,"whyStopped":4,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":92,"startDateStruct":94,"completionDateStruct":96,"leadSponsor":98,"locationsCount":101},"100401235","tcf-001-track-target-rare-cancer-knowledge-study-100401235","NCT04504604","TCF-001 TRACK (Target Rare Cancer Knowledge) Study","TRACK","INCLUSION CRITERIA\n\n* Provision of signed and dated informed consent form.\n* Stated willingness to comply with all study related blood draws and assessments for the duration of the study.\n* Individuals who are 18 years old or older at the time of consent.\n* Patients with a rare (fewer than 6 cases per 100,000 per year) solid tumor or lymphoma with evaluable disease at baseline. The complete list of included cancers are included in the study protocol; diseases not listed in the study protocol may be enrolled with the approval of the Principal Investigator.\n* May or may not have had qualifying (by Foundation Medicine) comprehensive genomic profiling before the present study. For those who have had qualifying comprehensive genomic profiling performed prior to the present study, the archival specimen tested must have been harvested within 18 months of the baseline visit (i.e. date of consent) of the present study.\n* Willingness to provide existing archived and\u002For newly collected tissue resulting from standard of care procedures and blood samples for genomic profiling. If the submitted sample is determined to be insufficient for testing, the patient will be considered to be a screen failure.\n* For archival tissue to be used for comprehensive genomic profiling for the present study, that specimen must have been harvested within 18 months of the baseline visit (i.e. date of consent) of the present study.\n* Willingness to provide clinical and medical information to the study team as required.\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0-2.\n* Ability to read, write and communicate in English.\n* Ability to review and sign a web-based informed consent form, or review and sign an informed consent form in treating physician office.\n* Resides within the United States.\n\nEXCLUSION CRITERIA\n\n* Participants who are unable to provide informed consent.\n* Participants who are 17 years of age or younger.\n* Participants who are unable to comply with the study procedures.\n* Known existence of an uncontrolled intercurrent illness including, but not limited to, psychiatric illness or social situations that would impair compliance with study requirements.\n* Concurrent active malignancy requiring treatment within 1 year of enrollment, at the discretion of treating physician.\n* Pregnancy or breastfeeding.\n* Any unlisted criteria at the discretion of the treating physician.",{"count":68,"type":21},400,[70],"NA","This open label, non-randomized, multi-center, pragmatic study aims to establish whether patients with rare tumors can benefit from matched molecular therapy as dictated by their next-generation sequencing (NGS) results.",[30,73,74],"Cholangiocarcinoma","Cancer of Unknown Primary Site",[76,77,78,79,80,81,82,83,84,85,86,87,88,89,90],"genomics","precision medicine","molecular tumor board","remote participation","targeted therapy","patient reported outcomes","understudied diseases","comprehensive genomic profiling","virtual","next generation sequencing","liquid biopsies","tumor biopsies","cell-free DNA","biomarker testing","solid tumors","2026-05-21",{"date":93,"type":51},"2026-05-26",{"date":95,"type":51},"2020-10-01",{"date":97,"type":21},"2028-12",{"name":99,"class":100},"TargetCancer Foundation","OTHER",1,{"id":103,"slug":104,"hasResults":11,"nctId":105,"briefTitle":106,"officialTitle":107,"acronym":108,"eligibilityCriteria":109,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":110,"targetDuration":112,"studyType":113,"phases":4,"briefSummary":114,"conditions":115,"keywords":4,"overallStatus":47,"whyStopped":4,"lastUpdateSubmitDate":117,"lastUpdatePostDateStruct":118,"startDateStruct":120,"completionDateStruct":122,"leadSponsor":124,"locationsCount":101},"100504760","molecularly-aided-stratification-for-tumor-eradication-research-100504760","NCT05852522","Molecularly Aided Stratification for Tumor Eradication Research","NCT MASTER Plattform Molecularly Aided Stratification for Tumor Eradication Research","NCT-MASTER","Inclusion Criteria:\n\nRare cancer (Incidence \\\u003C6\u002F100,000 persons\u002Fyear) or Rare subtype of a more common entity (case-by-case decision; example: pancreatic ductal adenocarcinoma without KRAS mutation)\n\nMetastatic and\u002For locally advanced cancer with no curative therapy option and indication for systemic therapy\n\nExclusion Criteria:\n\nSevere neurological or psychiatric disorder interfering with the ability to give oral and written informed consent",{"count":111,"type":21},10000,"10 Years","OBSERVATIONAL","NCT\u002FDKFZ\u002FDKTK MASTER is a prospective, continuously recruiting, multicenter observational study for biology-guided stratification of adults with rare cancers, including rare subtypes of common entities, using comprehensive molecular profiling, and clinical decision-making in a multidisciplinary molecular tumor board.",[30,116],"Multiomics","2025-02-28",{"date":119,"type":51},"2025-03-04",{"date":121,"type":51},"2018-11-11",{"date":123,"type":21},"2029-10",{"name":125,"class":100},"German Cancer Research Center"]